Reported Sunday, Bausch Health To Present Key Findings On Xifaxan's Impact On Hepatic Encephalopathy At ACG Annual Meeting
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (Rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Earnings Preview: BHC to Report Financial Results Post-market on October 30
$Bausch Health(BHC.US)$ is scheduled to release its financial results post-market on October 30 ET. Earnings PreviewAnalysts estimate $Bausch Health(BHC.US)$ to post revenue of USD2.42B for 2024Q3,
RBC Capital Maintains Bausch Health(BHC.US) With Hold Rating, Raises Target Price to $10
Express News | Bausch Health Companies Inc : RBC Raises Target Price to $10 From $8.5
Bausch Health (BHC) Reports Next Week: What to Expect